{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:19:36Z","timestamp":1791231576819,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We present a series of twelve patients, bearing a wide range of solid malignancies, who received either PD-L1 or a combination of PD-L1 and CTLA-4 inhibitors. Following immunotherapy administration, they exhibited the clinical signs indicative of renal toxicity, including increased serum creatinine levels, proteinuria, nephrotic syndrome and\/or hematuria. All patients underwent renal biopsy. Results: All cases demonstrated some degree of interstitial inflammation and tubular injury, while in five patients, glomerular alterations consistent with a specific glomerulopathy were also observed: secondary \u201clupus-like\u201d membranous glomerulopathy in two cases and membranoproliferative glomerulonephritis, IgA glomerulonephritis and secondary AA amyloidosis in each of the remaining three patients. The two patients with \u201clupus-like\u201d nephritis and the one with amyloidosis experienced nephrotic syndrome, while their creatinine was within normal range. In the remaining nine cases, deterioration of renal function was the main manifestation. Conclusion: Our findings harmonize with bibliographical data that identify tubulointerstitial nephritis as the most frequent histological lesion related to ICIs administration. The preferential involvement of tubulointerstitial tissue could be associated with the reported higher expression levels of PD-L1 on tubular epithelial cells, compared to glomeruli. On the other hand, glomerular involvement is probably a consequence of a systemic immune system reconstruction, induced by immune-checkpoints inhibition.<\/jats:p>","DOI":"10.3390\/jcm11164786","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T23:44:25Z","timestamp":1660693465000},"page":"4786","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immune Checkpoint Inhibitors\u2019 Associated Renal Toxicity: A Series of 12 Cases"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4728-7104","authenticated-orcid":false,"given":"Kostas","family":"Palamaris","sequence":"first","affiliation":[{"name":"First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-9360","authenticated-orcid":false,"given":"Dimitrios","family":"Alexandris","sequence":"additional","affiliation":[{"name":"Department of Oncology, Evaggelismos General Hospital of Athens, 10676 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-9421","authenticated-orcid":false,"given":"Kostas","family":"Stylianou","sequence":"additional","affiliation":[{"name":"Nephrology Department, Heraklion University Hospital, Voutes, 71500 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2210-6725","authenticated-orcid":false,"given":"Ioannis","family":"Giatras","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hygeia Hospital, 15123 Marousi, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stofas","sequence":"additional","affiliation":[{"name":"First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kaitatzoglou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hygeia Hospital, 15123 Marousi, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-2447","authenticated-orcid":false,"given":"Magda","family":"Migkou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-5884","authenticated-orcid":false,"given":"Dimitrios","family":"Goutas","sequence":"additional","affiliation":[{"name":"First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmia","family":"Psimenou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Theodoropoulou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tzaneio General Hospital of Pireaus, 18536 Pireas, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Theocharis","sequence":"additional","affiliation":[{"name":"First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-7467","authenticated-orcid":false,"given":"Nektarios","family":"Alevizopoulos","sequence":"additional","affiliation":[{"name":"Department of Oncology, Evaggelismos General Hospital of Athens, 10676 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Gerakis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hygeia Hospital, 15123 Marousi, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikleia","family":"Gakiopoulou","sequence":"additional","affiliation":[{"name":"First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","article-title":"Cardiorenal Complications of Immune Checkpoint Inhibitors","volume":"14","author":"Sury","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological Features of Acute Kidney Injury Associated with Immune Checkpoint Inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney Injuries Related to Ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of Acute Interstitial Nephritis with Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_6","first-page":"936","article-title":"Renal Effects of Immune Checkpoint Inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A Systematic Review of Immune Checkpoint Inhibitor\u2013Associated Glomerular Disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e27546","DOI":"10.1097\/MD.0000000000027546","article-title":"Pembrolizumab-Induced Focal Segmental Glomerulosclerosis: A Case Report","volume":"100","author":"Kim","year":"2021","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619147","DOI":"10.3389\/fimmu.2021.619147","article-title":"Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-018-0958-6","article-title":"Minimal Change Disease Associated with Anti-PD1 Immunotherapy: A Case Report","volume":"19","author":"Gao","year":"2018","journal-title":"BMC Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s13730-020-00462-0","article-title":"Pembrolizumab-Associated Nephrotic Syndrome Recovered from Transient Hemodialysis in a Patient with Lung Cancer","volume":"9","author":"Ishibuchi","year":"2020","journal-title":"CEN Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 Antibody-Induced Lupus Nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-Associated Minimal-Change Disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern. Med."},{"key":"ref_17","first-page":"1","article-title":"Nephrotoxicity of Immune Checkpoint Inhibitors beyond Tubulointerstitial Nephritis: Single-Center Experience 11 Medical and Health Sciences 1103 Clinical Sciences","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_18","first-page":"2638283","article-title":"Membranoproliferative Glomerulonephritis Associated with Nivolumab Therapy","volume":"2020","author":"Giehl","year":"2020","journal-title":"Case Rep. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00428-020-02882-w","article-title":"ANCA-Associated Pauci-Immune Necrotizing Glomerulonephritis during the Treatment with Pembrolizumab","volume":"478","author":"Uner","year":"2021","journal-title":"Virchows Archiv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e20464","DOI":"10.1097\/MD.0000000000020464","article-title":"Nivolumab-Induced IgA Nephropathy in a Patient with Advanced Gastric Cancer: A Case Report","volume":"99","author":"Tanabe","year":"2020","journal-title":"Medicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal Vasculitis and Pauci-Immune Glomerulonephritis Associated with Immune Checkpoint Inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2019.11.011","article-title":"C3 Glomerulonephritis in a Patient Treated with Anti\u2013PD-1 Antibody","volume":"125","author":"Ville","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"ICPi-AKI Consortium Investigators. Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti\u2212PD-1 Immunotherapy May Induce Interstitial Nephritis with Increased Tubular Epithelial Expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/ndt\/gfl818","article-title":"PD-L1 Partially Protects Renal Tubular Epithelial Cells from the Attack of CD8+ Cytotoxic T Cells","volume":"22","author":"Starke","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1440-1797.2006.00651.x","article-title":"Proton Pump Inhibitors and Acute Interstitial Nephritis: Report and Analysis of 15 Cases","volume":"11","author":"Simpson","year":"2006","journal-title":"Nephrology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cgh.2005.11.004","article-title":"Proton Pump Inhibitors and Acute Interstitial Nephritis","volume":"4","author":"Geevasinga","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1681\/ASN.2006050418","article-title":"Involvement of Drug-Specific T Cells in Acute Drug-Induced Interstitial Nephritis","volume":"17","author":"Spanou","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.025","article-title":"PD-1 Immunobiology in Systemic Lupus Erythematosus","volume":"97","author":"Curran","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000480641","article-title":"The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis","volume":"46","author":"Liao","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00005-017-0485-3","article-title":"The PD-1\/PD-L1 Inhibitory Pathway Is Altered in Primary Glomerulonephritides","volume":"66","author":"Grywalska","year":"2018","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/2399369320907598","article-title":"Immune Checkpoint Inhibitor\u2013Associated Renal Amyloid A Amyloidosis: A Case Series and Review of the Literature","volume":"4","author":"Lapman","year":"2020","journal-title":"J. Onco-Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CJI.0000000000000412","article-title":"Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management through Histopathologic Features","volume":"45","author":"Guarnieri","year":"2022","journal-title":"J. Immunother."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/16\/4786\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:10:38Z","timestamp":1760141438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/16\/4786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":36,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["jcm11164786"],"URL":"https:\/\/doi.org\/10.3390\/jcm11164786","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}